In their Article, Harpreet Wasan and colleagues¹ reported a combined analysis of three prospective randomised controlled trials (SIRFLOX, FOXFIRE, and FOXFIRE-Global) that compared a regimen of first-line leucovorin, fluorouracil, and oxaliplatin (FOLFOX) plus selective internal radiotherapy (SIRT) with yttrium-90 resin microspheres with FOLFOX alone in patients with colorectal cancer with liver metastases. They found no survival benefit for the FOLFOX plus SIRT group (median overall survival 22·6 months [95% CI 21·0–24·5] with FOLFOX plus SIRT vs 23·3 months [21·8–24·7] with FOLFOX alone; p=0·61).

中文翻译：

---

足够的SIRT活性剂量与足够的化疗剂量同等重要

Harpreet Wasan及其同事¹在其文章中报告了三项前瞻性随机对照试验（SIRFLOX，FOXFIRE和FOXFIRE-Global）的组合分析，该试验比较了一线亚叶酸，氟尿嘧啶和奥沙利铂（FOLFOX）方案与选择性内部放射疗法的方案（SIRT）单独使用FOLFOX的Yttrium-90树脂微球治疗患有肝转移的大肠癌患者。他们发现对FOLFOX加SIRT组没有存活益处（中位总体存活22·6个月[95％CI 21·0-24·5]与FOLFOX加SIRT VS 23·3个月[21·8-24·7]与单独使用FOLFOX； p = 0·61）。